SCHEMBL17040318

SCHEMBL17040318

CC(=O)c1ccc(Br)c(F)c1OCC(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 1/20 0.37
TAB1 Q15750 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36
ACACB O00763 6/20 0.35
HIF1A Q16665 1/20 0.35
LMNA P02545 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAOB P27338 3/20 0.34
MAOA P21397 2/20 0.34
GRM2 Q14416 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
SCN9A Q15858 1/20 0.33
NR1H4 Q96RI1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17040889 0.83 TSHR (0.42) ALDH1A1TSHRLMNAKMT2ASMN1; SMN2
SCHEMBL17040892 0.79 ALDH1A1 (0.40) ALDH1A1LMNARAB9AKMT2ASMN1; SMN2
SCHEMBL8012400 0.73 RXRA (0.34) ACACBLMNARAB9ASMN1; SMN2MAPT
SCHEMBL17041337 0.72 SCN4A (0.34) ALDH1A1TSHRLMNAMAOASCN9A
SCHEMBL17028323 0.71 MAP3K7 (0.39) MAP3K7TAB1
SCHEMBL17326567 0.71 PTGDR2 (0.50) ALDH1A1TSHRHIF1ALMNANPC1
SCHEMBL29345732 0.71 ALDH1A1 (0.51) ALDH1A1TSHRLMNANPC1RAB9A
SCHEMBL10640299 0.70 KDM4E (0.47) ALDH1A1ACACBHIF1ALMNAMAPT
SCHEMBL30484055 0.70 SMN1; SMN2 (0.38) ALDH1A1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL28635714 0.70 ERN1 (0.37) ALDH1A1KMT2ASMN1; SMN2MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3107900-B1 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES SERVIER LAB (FR) 2017-11-15 EP disclosed
US-9809553-B2 Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-11-07 US disclosed
US-9809553-B2 Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-11-07 US disclosed
US-20170137385-A1 ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-05-18 US disclosed
US-20170137385-A1 ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-05-18 US disclosed
WO-2015124877-A1 DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES LES LABORATOIRES SERVIER (FR) 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137385-A1 ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MYLK, MYLK2, MYLK3 MAP3K7 103/4885TAB1 2028/4885ALDH1A1 3415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.